gbola amusa md cfa head hc research
sale trade et
viral news genet medicin agtc xlrp updat show durabl cmv data
highlight week januari januari agtc buy announc data phase i/ii trial
aav-bas gene therapi x-link retin pigmentosa xlrp show durabl improv
visual function data patient report septemb show show stabl visual
function month patient dose peripher month dose central compani
provid updat central dose patient improv visual sensit report evalu patient
improv visual acuiti patient agtc plan start pivot trial end buy
announc updat mrna-bas vaccin cytomegaloviru cmv data phase trial
show increas neutral antibodi nab level follow administr vaccin
cmv seroposit seroneg individu nab level seroneg subject follow dose
higher baselin level seroposit individu compar increas follow dose
level seroposit individu higher baselin follow dose compar
increas fold dose unrat announc top-line result
phase i/ii studi gt ornithin transcarbamylas over-the-counter defici
compani report new data cohort long-term follow-up data cohort result cohort
show femal respond male requir longer follow-up femal patient show signific
consist reduct ammonia level cohort femal patient show signific percent reduct
ammonia level week previous report respond remain clinic metabol stabl
week patient report respons date treatment-rel seriou advers event
report though patient cohort elev alt level
look forward januari januari januari allianc regen medicin host
cell gene therapi state industri brief san francisco agenda includ askbio unrat atara
weekli price move vivo genet medicin aav srna mrna vivo gene edit
upcom chardan genet medicin event contact chardan rsvp
gene express continu need diagnosi genet disord
senat susan collin r-me announc introduct bipartisan legisl better enabl genet test
children rare diseas legisl part end diagnost odyssey act origin
introduc august would allow state conduct pilot program provid whole genom sequenc
wg servic children medicaid suspect genet diseas program would increas feder
medic assist percentag rate fmap help provid servic wg diagnost purpos receiv
support nih director franci collin wrote need tool make quick diagnost decis new
technolog enabl autom sampl collect data process
altern whole genom sequenc whole exom sequenc sequenc wg cover
genom though we cover code region cover genom nonetheless we
less complic less expens perform fda issu guidelin next gener sequencing-bas
pleas refer import disclosur inform regul analyst certif found page report
vitro diagnost rapid pace innov field led compani includ unrat bgi
genom privat wg may advanc becom cheaper wide adopt
drop coverag medicin compani novarti unrat announc januari
complet tender offer outstand share common stock medicin compani
buy dose system crispr therapi januari livshit
intellia announc anticip mileston provid updat pipelin program name
compani track ind submiss attr nomin develop cell
therapi candid wt aml announc hereditari angioedema develop program
deliv crispr compon lipid nanoparticl would system crispr therapi
dose human
intellia entri interest move build directli program
visibl program intellia plan present preclin data plan nomin
develop candid
buy updat ind file mma takeda collab cn januari livshit
logicbio announc file ind lead nuclease-fre genom edit asset
methylmalon acidemia mma establish research collabor
unrat develop program crigler-najjar syndrom cn
takeda collabor takeda provid research fund program exchang
exclus option negoti exclus world-wide licens see deal extern valid
logicbio genom edit platform mean logicbio longer publicly-trad genom edit compani
buy increment data progress cmv januari livshit
report progress mrna-bas cytomegaloviru cmv vaccin announc updat
data phase studi show continu increas neutral antibodi level
vaccin commenc dose random control phase ii studi well estim timelin
phase ii data phase trial initi
see continu increas neutral antibodi titer month posit signal durabl
program particularli titer kinet track close initi phase cohort year follow-up
anticip data phase ii dose-confirm studi inform dose select plan pivot
phase expect enrol individu
vblt buy leadership callmov catalyst-rich januari livshit
januari chardan host leadership call vbl manag key takeaway
event
 investor may cautiou vblt fail phase globe gbm trial clinician
 vbl multipl clinic readout includ phase oval trial mean multipl potenti
show enthusiasm asset gbm elsewher
inflect point clearer understand function
 market may yet focus potenti ind file aim toward strateg
partnership mean program may begin add valu year
genet medicin news januari januari
unrat updat partnership unrat arenaviru hiv hbv vaccin januari
xon unrat announc orphan drug design ultracar-t aml januari
buy announc appoint jame hassard chief commerci offic januari
nv unrat announc complet tender offer mdco unrat share januari
unrat announc updat clinic oper januari
tng fp unrat announc nec tse clinic trial therapeut cancer vaccin januari
page
sln gb unrat announc technolog evalu agreement takeda unrat sirna januari
unrat announc overview oper mileston januari
unrat announc appoint laurenc turka md chief scientif offic januari
vblt buy announc public pi/ii piii trial gbm januari
arct buy announc appoint steve hugh md chief develop offic januari
trvx unrat announc agreement iovaxi privat cancer vaccin januari
aruv privat announc receipt rpdd lentivir gt sickl cell diseas januari
arct buy announc appoint steve hugh md chief develop offic januari
agtc buy announc data pi/ii studi aav-bas gt xlrp januari
buy announc appoint michel robertson chief offic januari
announc plan initi pivot program test subretin deliveri gt
wet assess patient cohort phase i/iia trial
addit phase ii trial suprachoroid deliveri treatment wet diabet retinopathi
expect begin
compani announc fda remov partial clinic hold phase i/iia trial subretin deliveri
wet
interim data phase i/ii trial gt mp ii expect
gt phase i/ii trial hofh expect
buy announc dr coffin phd pre chief philip astley-spark ceo januari
 melbourn publish antigen depend activ gamma delta cell januari
unrat announc result pi/ii studi aav-bas gt over-the-counter defici januari
genethon privat announc collab unrat aav-bas gt dmd januari
buy announc roll bla rnai-bas lumasiran primari hyperoxaluria type januari
passag privat announc appoint sandip kapadia board director januari
buy announc chang organ structur focu develop januari
unrat announc partnership unrat gt manufactur januari
unrat initi unrat piii trial akcea-ttr-lrx attr cardiomyopathi januari
pact pharma privat announc mm seri tcr-t cell therapi januari
neutral announc data pi trial gt wet januari
compani mention report
page
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma buy lysogen oncosec medic oxford biomedica neutral vbl buy
figur select price movement week end jan vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm appli genet therapytickerratingccm ptupsideclosechang changemc mm arcturu gene editingtickerratingccm ptupsideclosechang changemc mm precis pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note though avx nite acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap pharmaceut
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdiluteddil mcpercentccm ptshare mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid taysha gene therapi pharmaceut
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name bntx model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani pharmaceut
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
swedish orphan biovitrum astrazeneca
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
price prv
page
date fda rpdd
ultragenyx genetx
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genetx ultragenyx
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
